FEATURED CONTENT

• An Adaptable, Intelligent Centerpiece For Customizable Manufacturing

  Data from a CAR T cell manufacturing case study challenges the assumption that automated cell processing platforms and third-party expansion technologies are inherently incompatible.

• Reducing Cost Drivers And Improving Efficiency In CAR T Cell Manufacturing

  Fragmented CAR T cell manufacturing workflows drive up costs and extend timelines. This case study quantifies what consolidating manufacturing and QC through automation actually delivers.

• A End-To-End Solution For Robust Large-Scale CAR T Manufacturing

  Automated, closed-system workflows are reshaping CAR T manufacturing, compressing multi-week processes into days while preserving critical functional attributes of the final cell product.

• How Collaborative Preparation Drives Optimal Tech Transfer Execution

  Tech transfer missteps risk higher costs and lower product quality. Success hinges on a clear sponsor strategy and working with an experienced, collaborative CDMO.

• Streamline Analytical Tech Transfer Through Analytical Target Profile

  Analytics debt in CGT can derail timelines and budgets. Learn how early ATP planning and cross-functional alignment can eliminate costly setbacks and accelerate IND approvals.

• Enhancing Preclinical Cell Therapy Development

  Automation in cell therapy development boosts reproducibility, reduces error, and enhances yield. Learn how it’s reshaping preclinical workflows and accelerating clinical trial readiness.

• Streamline Analytical Tech Transfer Through ATP Diligence And Standardization

  Early-stage assays not guided by a detailed analytical target profile often reach QC with missing controls, undefined sample-suitability limits, and protocols that need a GMP overhaul.

• The Power Of A Platform Process For Lentiviral Vectors

  A robust platform process can help ensure therapeutic efficacy and supply chain security for LVV-based products, as well as support aggressive development and commercialization timelines.

• Enhancing Cell And Gene Therapy: The LVV Platform Advantage

  Many drug development platforms focus solely on cost reduction or improved process efficiency, offering few, if any, solutions to bolster biological performance.